| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba59995a3ee9e6980c38a9aa783024a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16043 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 |
| filingDate |
2018-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c9ba989074f34ab88e6006b34c229e |
| publicationDate |
2020-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020056203-A1 |
| titleOfInvention |
Treating Animal Cancers Through Programmed Cancer Cell Death |
| abstract |
The present invention provides systems and methods wherethrough a cancer cell's metabolic activities attract a vector to the cell to provide the cell with tools and instructions for self-destruction. A vector is engineered for attraction to and reaction with cells of higher temperature, a characteristic result of hypermetabolism inherent in the uncontrolled or extreme growth of cancerous and precancerous cells. A second engineered feature relates to the increased acidity resulting from a cancer cell's reduced reliance of mitochondrial ATP production. The engineered vector then stimulates the body's natural intracellular and extracellular innate immune responses to effect death and destruction of the targeted hypermetabolizing cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112494427-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113264978-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111647610-A |
| priorityDate |
2018-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |